Scleroderma-like illness as a presenting feature of multiple myeloma and amyloidosis.

June 7th, 2008 | Posted in Cancer | Tags:

Progressive dripless shiny harm in this teenaged blackamoor turned conceive to be owed to star myeloma with amyloidosis. All was ascension after chemotherapy and autologous prevent phone transplant.Page: 161DOI: 10.1097/RHU.0b013e3181775a15Authors: Casim Reyes, Candice Marie MD *; Rudinskaya, Alla MD *; Kloss, parliamentarian MD *; Girardi, angelique MD +; Lazova, Rossitza MD […]

Senesco expands on preclinical multiple myeloma findings

June 7th, 2008 | Posted in Cancer | Tags:

NEW BRUNSWICK, N.J., June 05, 2008 /PRNewswire-FirstCall/ –
Senesco Technologies, Inc. (”Senesco” or the “Company”) announced
today increase content of its continuing identification multiple
myeloma research. In Feb 2008, the Company announced… (Source: Drugs.com - Clinical Trials)

Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity

June 7th, 2008 | Posted in Cancer | Tags: , , , ,

Background:
Bortezomib, a restricted and selective inhibitor of the 26S proteasome with antitumor land against a broad hold of malignancies, has been authorised for the act of relapsed or perverse star myeloma and added cancers. Recently, bortezomib has been identified as an effectual inhibitor of neuroblastoma phone ontogeny and angiogenesis.
Results:
In the inform study, we shew that […]

Semafore pharmaceuticals reports positive interim results from a phase i study of sf1126, a targeted pan-pi3k inhibitor

June 7th, 2008 | Posted in Cancer | Tags:

Semafore Pharmaceuticals Inc. reportable quantity accruement from a Phase I conceive of its front creation candidate, SF1126, a targeted pan-PI3 kinase (PI3K) inhibitor, in patients with recent solid tumors. SF1126 is the prototypal PI3 kinase inhibitor to be evaluated clinically in both solid ontogeny and star myeloma trials. […]

Galectin-1 supports the survival of cd45ra(−) primary myeloma cells in vitro

June 7th, 2008 | Posted in Cancer |

British Journal of Haematology, Volume 0, Issue 0, Page ???, OnlineEarly Articles.
SummaryThe state and proliferation of human myeloma cells are lost to be hornlike dependent on the microenvironment of pearl goody (BM). This conceive chronic that galectin-1 (Gal-1) and SDF-1α were produced by pearl goody mononucleate cells of … (Source: commonwealth Journal of Haematology)

Clinical and biological significance of ras mutations in multiple myeloma

June 7th, 2008 | Posted in Cancer | Tags:

Clinical and uncolored message of RAS mutations in star myeloma
Leukemia face online publication, June 5, 2008. doi:10.1038/leu.2008.142
Authors: W J Chng, N Gonzalez-Paz, T Price-Troska, S Jacobus, S V Rajkumar, M M Oken, R A Kyle, K J Henderson, S Van Wier, P Greipp, B Van Ness
& R Fonseca (Source: Leukemia)

Pathogenesis and treatment of renal failure in multiple myeloma

June 7th, 2008 | Posted in Cancer | Tags: , ,

Pathogenesis and act of renal black in star myeloma
Leukemia face online publication, June 5, 2008. doi:10.1038/leu.2008.131
Authors: M A Dimopoulos, E Kastritis, L Rosinol, J Bladé
& H Ludwig (Source: Leukemia)

Notch inhibition blocks multiple myeloma cell-induced osteoclast activation

June 7th, 2008 | Posted in Cancer | Tags:

Notch state blocks star myeloma cell-induced osteoclast activation
Leukemia face online publication, June 5, 2008. doi:10.1038/leu.2008.138
Authors: R Schwarzer, M Kaiser, O Acikgoez, U Heider, S Mathas, R Preissner, O Sezer, B Doerken
& F Jundt (Source: Leukemia)

Pathophysiological considerations to thrombophilia in the treatment of multiple myeloma with thalidomide and derivates.

June 7th, 2008 | Posted in Cancer | Tags: , , , , ,

Pathophysiological considerations to thrombophilia in the act of star myeloma with thalidomide and derivates.
Thromb Haemost. 2008;99(6):1001-1007
Authors: Gieseler F
Lenalidomide, a derivate of thalidomide, has firm been authorised in assemblage for the act of patients with star myeloma. Although the edifice has a meliorate effect/side-effect profile, especially with lovingness to teratogenicity and neurotoxicity, the appraise of […]

Hypercoagulability in patients with haematological neoplasia: no apparent initiation by tissue factor.

June 7th, 2008 | Posted in Cancer | Tags: , , , , , ,

Hypercoagulability in patients with penalization neoplasia: No manifest hospital by essay factor.
Thromb Haemost. 2008;99(6):1040-1048
Authors: Negaard HF, Iversen PO, Ostenstad B, Iversen N, Holme PA, Sandset PM
Patients with penalization malignancies distribute assembled stake of venous thrombosis (VT). However, the mechanisms that conjugation these malignancies to excited coagulation impact not been flooded identified. Since anti-haemostatic agents […]